You are here

FDA Grants Fast Track Designation for Smallpox Vaccine Candidate Imvamune

COPENHAGEN, Denmark, July 21/PRNewswire/ -- Bavarian Nordic today announces that it has received fast track designation by the US Food and Drug Administration for its Investigational New Drug Application covering the company's third generation smallpox vaccine candidate IMVAMUNE(TM) (MVA-BN(R)). IMVAMUNE(TM) is the first and only smallpox vaccine candidate to receive this designation.

The fast track designation gives priority review status to a license application and allows filing portions of license applications ahead of others. It facilitates frequent and ongoing communication with the FDA and is intended to facilitate development and expedite the review of new therapies that are intended to treat serious or life-threatening conditions.

Bavarian Nordic is currently conducting an extensive clinical development programme with its third generation vaccine candidate IMVAMUNE(TM). Ongoing studies are designed to evaluate the immune response of the vaccine in comparison to Dryvax(R) as well to evaluate the vaccine in special populations for which Dryvax(R) is contraindicated.

Peter Wulff, President and CEO of Bavarian Nordic, said, "We are pleased with the fast track designation for IMVAMUNE(TM), which recognises the importance of developing a safer smallpox vaccine. The fact that IMVAMUNE(TM) is the first and only smallpox vaccine candidate that has received fast track designation confirms that IMVAMUNE(TM) is the leading candidate for the development of a safer smallpox vaccine."

This fast track designation follows other key successes including the recent signing of an agreement with GlaxoSmithKline for the production and marketing of IMVAMUNE(TM) and the grant of a patent covering the company's MVA-BN(R) virus and associated technology. Together, these milestones demonstrate Bavarian Nordic's position as the leading developer of next generation smallpox vaccines.

Source: Bavarian Nordic

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications